よきにはからえ 尼百会ぢうはち
- カテゴリ：日記
- 2024/12/17 09:39:03
decembre 9 lunedi ☁︎❄︎ 7/1℃
doctor X
A new drug to treat amyotrophic lateral sclerosis, or ALS, has cleared a major hurdle on the path to being produced and sold in Japan. An expert panel at the health ministry on Monday gave the green light to “tofersen.” The drug was developed by U.S. pharmaceutical company Biogen. The next step will be formal approval by the ministry. ALS is a neurological disorder that causes progressive muscle weakness. It affects an estimated 10,000 people in Japan. Officials at the firm's Japan arm say the drug is for ALS patients with a mutation in a specific gene called “SOD1” that accounts for about 2 percent of ALS cases. Scientists say the mutations cause the creation of abnormal proteins and lead to symptoms. Tofersen is expected to prevent the production of such harmful proteins. Experts say the new drug will be the first for use in Japan that addresses an underlying cause of ALS.
